Palatin Technologies Inc (LTS:0KF3)

$ 1.1216 0.0122 (1.1%) Market Cap: 22.48 Mil Enterprise Value: 20.57 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 50/100

Q1 2025 Palatin Technologies Inc Earnings Call Transcript
Nov 14, 2024

$1.05 (-13.28%)

Earnings
Q4 2024 Palatin Technologies Inc Earnings Call Transcript
Oct 01, 2024

$0.9005 (+0.61%)

Earnings
Q3 2024 Palatin Technologies Inc Earnings Call Transcript
May 15, 2024

$2.08 (-6.86%)

Earnings
Palatin Technologies Inc To Discuss PL9643 Phase 3 Clinical Study Results Transcript
Feb 28, 2024
Q2 2024 Palatin Technologies Inc Earnings Call Transcript
Feb 15, 2024

$3.24 (-21.81%)

Earnings
Q1 2024 Palatin Technologies Inc Earnings Call Transcript
Nov 14, 2023

$1.92

Earnings
Q4 2023 Palatin Technologies Inc Earnings Call Transcript
Sep 28, 2023

$1.51 (-8.48%)

Earnings
Q3 2023 Palatin Technologies Inc Earnings Call Transcript
May 16, 2023

$2.42 (+10.50%)

Earnings
Palatin Technologies Inc To Host Key Opinion Leader Webinar Transcript
May 08, 2023
Q2 2023 Palatin Technologies Inc Earnings Call Transcript
Feb 15, 2023

$3.18

Earnings
Q1 2023 Palatin Technologies Inc Earnings Call Transcript
Nov 14, 2022

$4.61 (-1.21%)

Earnings
Q4 2022 Palatin Technologies Inc Earnings Call Transcript
Sep 22, 2022

$7.97

Earnings
Q3 2022 Palatin Technologies Inc Earnings Call Transcript
May 17, 2022

$9

Earnings
Palatin Technologies Inc To Host Key Opinion Leader Webinar Transcript
Mar 07, 2022
Q2 2022 Palatin Technologies Inc Earnings Call Transcript
Feb 15, 2022

$10.43

Earnings
Q1 2022 Palatin Technologies Inc Earnings Call Transcript
Nov 15, 2021

$10.1

Earnings
Q4 2021 Palatin Technologies Inc Earnings Call Transcript
Sep 29, 2021

$11.63

Earnings
Palatin Technologies Inc Annual Shareholders Meeting Transcript
Jun 08, 2021
Palatin Technologies Inc Key Opinion Leader Webinar Transcript
May 21, 2021
Q3 2021 Palatin Technologies Inc Earnings Call Transcript
May 17, 2021

$13.13 (-0.94%)

Earnings
Q2 2021 Palatin Technologies Inc Earnings Call Transcript
Feb 17, 2021

$22.65 (-19.48%)

Earnings
Palatin Technologies, Inc. - Special Call Transcript
Dec 15, 2020
Q1 2021 Palatin Technologies Inc Earnings Call Transcript
Nov 17, 2020

$11.02

Earnings
Q4 2020 Palatin Technologies Inc Earnings Call Transcript
Sep 28, 2020

$13.25

Earnings
Palatin Technologies Inc Vyleesi Update Call Transcript
Jul 27, 2020
Palatin Technologies Inc Annual Shareholders Meeting (Part 2) Transcript
Jul 23, 2020
Palatin Technologies Inc Annual Shareholders Meeting Transcript
Jun 25, 2020
Q3 2020 Palatin Technologies Inc Earnings Call Transcript
May 12, 2020

$16.75

Earnings
Q2 2020 Palatin Technologies Inc Earnings Call Transcript
Feb 11, 2020

$16.75

Earnings
Q1 2020 Palatin Technologies Inc Earnings Call Transcript
Nov 13, 2019

$26.5

Earnings
Q4 2019 Palatin Technologies Inc Earnings Call Transcript
Sep 12, 2019

$26

Earnings
Q3 2019 Palatin Technologies Inc Earnings Call Transcript
May 09, 2019

$29.5

Earnings

Palatin Technologies, Inc. - Special Call Transcript

Dec 15, 2020 / 01:00PM GMT

Release Date Price: $10.61 (-3.74%)

Transcript

Operator

Good morning, ladies and gentlemen, and welcome to the Palatin PL-9643 Phase II Dry Eye Disease Clinical Trial Results Call. Before we begin our remarks, I would like to remind you that statements made by Palatin that are not historical facts may be forward-looking statements.

These statements are based on assumptions that may or may not prove to be accurate, and actual results may differ materially from those anticipated, due to a variety of risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission.

Please consider such risks and uncertainties carefully in evaluating forward-looking statements and Palatin's prospects. Now I'd like to turn the call over to today's host, Dr. Carl Spana, President and Chief Executive Officer of Palatin Technologies. Sir, please go ahead.

Carl Spana

Palatin Technologies, Inc. - Co-Founder, President, CEO & Director

Thank you. Good morning, and welcome to the PL-9643 Phase II Dry Eye Disease Clinical Trial Results Call. I am Dr. Carl Spana. I'm CEO and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.